
Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review
Description
Celltrion Inc (068270) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has an operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea.
Celltrion Inc Key Recent Developments
Jan 14,2025: Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline at the 43rd Annual j.p. Morgan Healthcare Conference
Sep 24,2024: Pinotbio Receives First Milestone in Celltrion ADC Platform Agreement
Jul 17,2024: Celltrion Remsima SC Surpasses 20% Market Share across Europe Successfully Established as a Key Treatment for Autoimmune Diseases
Jun 27,2024: Celltrion Publishes ESG Report '100% Reduction of Direct and Indirect Greenhouse Gases by 2045'
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has an operational presence in Korea, Russia, the UK, and the US. Celltrion is headquartered in Incheon, South Korea.
Celltrion Inc Key Recent Developments
Jan 14,2025: Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline at the 43rd Annual j.p. Morgan Healthcare Conference
Sep 24,2024: Pinotbio Receives First Milestone in Celltrion ADC Platform Agreement
Jul 17,2024: Celltrion Remsima SC Surpasses 20% Market Share across Europe Successfully Established as a Key Treatment for Autoimmune Diseases
Jun 27,2024: Celltrion Publishes ESG Report '100% Reduction of Direct and Indirect Greenhouse Gases by 2045'
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note:Some sections may be missing if data is unavailable for the company
Table of Contents
52 Pages
- Section 1 - About the Company
- Celltrion Inc - Key Facts
- Celltrion Inc - Key Employees
- Celltrion Inc - Key Employee Biographies
- Celltrion Inc - Major Products and Services
- Celltrion Inc - History
- Celltrion Inc - Company Statement
- Celltrion Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Section 2 – Company Analysis
- Company Overview
- Celltrion Inc - Business Description
- Business Segment: Biopharmaceutical Medicines
- Overview
- Performance
- Business Segment: Chemical Medicines
- Overview
- Performance
- Geographical Segment: Asia
- Performance
- Geographical Segment: Domestic Market
- Performance
- R&D Overview
- Celltrion Inc - Corporate Strategy
- Celltrion Inc - SWOT Analysis
- SWOT Analysis - Overview
- Celltrion Inc - Strengths
- Celltrion Inc - Weaknesses
- Celltrion Inc - Opportunities
- Celltrion Inc - Threats
- Celltrion Inc - Key Competitors
- Section 3 – Company Financial Ratios
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Section 4 – Company’s Lifesciences Financial Deals and Alliances
- Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Celltrion Inc, Recent Deals Summary
- Section 5 – Company’s Recent Developments
- Jan 14, 2025: Celltrion Unveils Strategic Vision for Advancing Its Innovative Drug Pipeline at the 43rd Annual j.p. Morgan Healthcare Conference
- Sep 24, 2024: Pinotbio Receives First Milestone in Celltrion ADC Platform Agreement
- Jul 17, 2024: Celltrion Remsima SC Surpasses 20% Market Share across Europe Successfully Established as a Key Treatment for Autoimmune Diseases
- Jun 27, 2024: Celltrion Publishes ESG Report '100% Reduction of Direct and Indirect Greenhouse Gases by 2045'
- Jun 20, 2024: Celltrion Won the bid for the French University Hospital Association... Accelerating prescription in all areas such as cancer and autoimmune diseases
- May 09, 2024: Celltrion to Achieve KRW 737 Billion in Sales in Q1 2024 Record Sales
- May 02, 2024: Celltrion Ramsima and Herzuma Win Bid for Peruvian Public Institution
- Feb 15, 2024: Celltrion’s 3 Therapeutics Succeeded in Winning Bids from Peruvian Public Institutions
- Jan 18, 2024: Celltrion Expands Bidding Performance for 3 Anti-Cancer Drugs in Major European Countries
- Jan 12, 2024: Celltrion’s Autoimmune Disease Treatment Expands Bids in Major European Countries
- Section 6 – Appendix
- Methodology
- Ratio Definitions
- About GlobalData
- Contact Us
- Disclaimer
- List of Tables
- Celltrion Inc, Key Facts
- Celltrion Inc, Key Employees
- Celltrion Inc, Key Employee Biographies
- Celltrion Inc, Major Products and Services
- Celltrion Inc, History
- Celltrion Inc, Subsidiaries
- Celltrion Inc, Key Competitors
- Celltrion Inc, Ratios based on current share price
- Celltrion Inc, Annual Ratios
- Celltrion Inc, Annual Ratios (Cont...1)
- Celltrion Inc, Annual Ratios (Cont...2)
- Celltrion Inc, Interim Ratios
- Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Year, 2019 to YTD 2025
- Celltrion Inc, Pharmaceuticals & Healthcare, Deals By Type, 2019 to YTD 2025
- Celltrion Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.